Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

Broadcast Retirement Network's Jeffrey Snyder discusses the state of investment in the life sciences with scientist and ...

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA ...

This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

The biotechnology company said in its statement to the ASX that the US Food and Drug Administration (FDA) had granted ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

The U.S. excels at funding discovery and celebrating breakthroughs, then neglects the hard work of manufacturing them at ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.